Inovio Pharmaceuticals, Inc. — Q1 2016 Form 10-Q
Business context and reporting period
Quarter ended March 31, 2016. Inovio is a clinical-stage biotechnology company developing DNA immunotherapies and vaccines with electroporation delivery technology. It had no product sales; revenue came from collaborations, grants and government contracts. Financial statements are unaudited.
Financial performance and liquidity
- Revenue: $8.1 million, up 57% from $5.2 million in Q1 2015. Grant and miscellaneous revenue rose to $6.2 million from $0.8 million, largely reflecting the DARPA Ebola award and a University of Pennsylvania subcontract. Collaboration revenue declined to $1.9 million from $4.4 million, mainly because Q1 2015 included Roche revenue recognized after partial termination of its agreement.
- Operating results: R&D expense increased 93% to $18.2 million; general and administrative expense rose 31% to $5.4 million. Operating loss widened to $15.5 million from $8.4 million. Net loss narrowed to $8.0 million from $10.6 million, or $0.11 per share versus $0.17, primarily due to a $7.5 million gain on the GeneOne investment.
- Cash flow: Cash used in operations was $15.7 million, compared with $12.1 million in Q1 2015. Cash and cash equivalents fell to $41.6 million from $57.6 million at year-end; cash plus short-term investments totaled $146.8 million.
- Liquidity and liabilities: Working capital was $127.2 million. Total liabilities were $40.1 million, including a $1.7 million common-stock warrant liability. The filing does not identify conventional borrowings in the presented balance sheet. Gross margin is not reported and is not a meaningful product-sales measure at this development stage.
- Other balance-sheet items: Total assets were $211.3 million and accumulated deficit was $369.1 million. Shares outstanding were 72.3 million at quarter-end; 73.1 million were outstanding May 2, 2016.
Material changes versus Q1 2015
- Higher grant revenue more than offset lower collaboration revenue, increasing total revenue.
- R&D spending rose substantially, attributed to DARPA-related work, clinical study costs and increased headcount; G&A also increased.
- Operating loss worsened, while net loss improved because of the GeneOne fair-value gain; this investment-related gain is distinct from operating performance.
- Cash and short-term investments decreased by approximately $16.2 million from December 31, 2015.
Outlook, commentary, risks and unusual items
- Management expected current cash and short-term investments to meet planned working-capital needs for at least the next 12 months, while stating that substantial losses would continue for some time. The company was evaluating collaborations as another funding source.
- Management planned to launch a Phase III study of its HPV-related product in 2016. All human product candidates remained in R&D, and the company did not expect product-sale revenue for at least several years.
- MedImmune funded development of INO-3112 and had made a $27.5 million upfront payment in 2015; up to $700 million in future event-based payments and tiered royalties were contingent on development, regulatory and commercial outcomes. Roche continued collaboration on INO-1800 after returning rights to INO-5150.
- DARPA revenue included $4.6 million in the quarter. Further funding under the grant depended on specified milestones and options.
- After quarter-end, Inovio acquired Bioject assets on April 29, 2016, paying $4.3 million in stock and $1.2 million in cash. A March 2016 Wistar research agreement provides for reimbursement of costs up to $3.1 million over five years.
- Key risks include clinical and regulatory failure or delay, manufacturing challenges, dependence on a limited number of collaborators and government awards, continuing cash burn and potential need for additional financing. The filing reports no material litigation and no material change to the risk factors in the 2015 Form 10-K.
Important facts for investors to verify
- Whether the planned 2016 Phase III study began on schedule and subsequent clinical results and regulatory progress.
- Cash burn, grant and collaboration collections, and whether liquidity remains adequate beyond management’s stated 12-month horizon.
- The timing and conditions for MedImmune, Roche and DARPA payments, including contingent milestones and options.
- The sustainability of revenue growth given the large contribution from grants and the one-time timing effects in collaboration revenue.
- The valuation sensitivity of the GeneOne investment gain and warrant liability, and the cash and dilution impact of the Bioject acquisition.